Stock Scorecard



Stock Summary for Celcuity Inc (CELC) - $100.42 as of 2/6/2026 4:11:37 PM EST

Total Score

4 out of 30

Safety Score

44 out of 100

Currently on the following lists
None
Tim's Recommendation
Avoid

Growth List Algorithm Criteria for CELC

Positive Quarterly and Annual earnings growth
P/E ratio less than Industry P/E Ratio
P/E ratio less than Sector P/E Ratio
P/E ratio that is half the Annual earnings growth rate (or less)
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Positive net income past year and 12 trailing months
Free cash flow ratio greater than 0 and less than 10

Small Cap List Algorithm Criteria for CELC

Revenue growing by at least 20% average per year over the last 5 years
Market Capitalization under 2 billion
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year

Dividend List Algorithm Criteria for CELC

Declared an ex-dividend date
Forward annual dividend rate greater than 2
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Current ratio most recent quarter greater than 2
Cash Flow per Share greater than Trailing Dividend Rate

Bonus Criteria for CELC

P/E ratio less than five-year Average P/E ratio
Last Price to 52 Week Low Ratio Less Than 1
Total Cash Per Share > Last Day Price
P/S Ratio < 1
P/B Ratio < 1

Safety Rating Criteria for CELC (44 out of 100)

Stock Price Rating (Max of 10) 10
Historical Stock Price Rating (Max of 10) 5
Stock Price Trend (Max of 10) 10
Book Value (Max of 10) 3
Book Value to Price (Max of 10) 0
Analyst Buy Ratings (Max of 5) 5
Analyst Strong Buy Ratings (Max of 5) 3
Dividend Yield Percentage (Max of 10) 0
Operating Margin (Max of 10) 0
Trading Volume (Max of 10) 8
Price to Earnings (Max of 10) 0
Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) 0

Latest News for for CELC

Director Sells 20,000 Celcuity Shares for $2.4 Million Following 933% Share Price Jump 2/6/2026 9:52:00 PM
Wolfe Research recommends buying Celcuity stock on weakness related to external catalyst 2/4/2026 3:28:00 PM
Celcuity to Present at Upcoming Guggenheim Emerging Outlook: Biotech Summit 2026 2/4/2026 12:28:00 PM
Celcuity to Present at Upcoming Guggenheim Emerging Outlook: Biotech Summit 2026 2/4/2026 11:59:00 AM
Celcuity (CELC) Draws Investor Attention as Precision Oncology Strategy Advances 2/2/2026 2:58:00 PM
Behavioral Patterns of CELC and Institutional Flows 2/1/2026 5:01:00 PM
Atle Fund Management AB Takes $1.84 Million Position in Celcuity, Inc. $CELC 2/1/2026 11:01:00 AM
Celcuity (NASDAQ:CELC) Director Sells $2,400,600.00 in Stock 1/30/2026 11:58:00 AM
Celcuity (CELC) Is Up 11.3% After FDA Grants Priority Review To Gedatolisib NDA - What's Changed 1/28/2026 11:58:00 AM
Celcuity (CELC) Is Up 11.3% After FDA Grants Priority Review To Gedatolisib NDA - What's Changed 1/28/2026 8:58:00 AM

Financial Details for CELC

Company Overview

Ticker CELC
Company Name Celcuity Inc
Country USA
Description Celcuity LLC is a forward-thinking clinical-stage biotechnology company headquartered in Minneapolis, Minnesota, dedicated to transforming cancer treatment through its proprietary technology platform. The company specializes in identifying specific cancer subtypes and developing targeted therapies, which allows for personalized treatment solutions tailored to individual patients' biological markers. With a strong drug development pipeline and a commitment to precision medicine, Celcuity is well-positioned to drive significant advancements in oncology and address unmet patient needs, establishing itself as a vital contributor in the dynamic field of cancer care.
Sector Name HEALTHCARE
Industry Name BIOTECHNOLOGY
Most Recent Quarter 9/30/2025
Next Earnings Date 3/19/2026

Stock Price History

Last Day Price 100.42
Price 4 Years Ago 14.01
Last Day Price Updated 2/6/2026 4:11:37 PM EST
Last Day Volume 896,696
Average Daily Volume 732,107
52-Week High 120.31
52-Week Low 7.58
Last Price to 52 Week Low 1,224.80%

Valuation Measures

Trailing PE N/A
Industry PE 26.47
Sector PE 152.45
5-Year Average PE -12.07
Free Cash Flow Ratio 62.76
Industry Free Cash Flow Ratio 13.67
Sector Free Cash Flow Ratio 27.03
Current Ratio Most Recent Quarter 12.26
Total Cash Per Share 1.60
Book Value Per Share Most Recent Quarter 2.70
Price to Book Ratio 42.56
Industry Price to Book Ratio 48.56
Sector Price to Book Ratio 51.46
Price to Sales Ratio Twelve Trailing Months 0.00
Industry Price to Sales Ratio Twelve Trailing Months 9.10
Sector Price to Sales Ratio Twelve Trailing Months 13.39
Analyst Buy Ratings 9
Analyst Strong Buy Ratings 1

Share Statistics

Total Shares Outstanding 46,271,300
Market Capitalization 4,646,563,946
Institutional Ownership 87.09%

Dividends

Ex-Dividend Date N/A
Previous Dividend Amount 0.0000
Current Dividend Amount 0.0000
Total Years Dividend Increasing N/A
Trailing Annual Dividend Rate 0.00
Trailing Annual Dividend Yield 0.00%
Forward Annual Dividend Rate 0.00
Forward Annual Dividend Yield 0.00%
5-Year Dividend Payments Count 0
3-Year Average Dividend Yield 0.00%
5-Year Average Dividend Yield 0.00%
1-Year Dividend Growth Rate Percentage 0.00%
3-Year Dividend Growth Rate Percentage 0.00%
5-Year Dividend Growth Rate Percentage 0.00%
All-Time Dividend Growth Rate Percentage 0.00%
Dividend Payout Ratio N/A

Income Statement

Quarterly Earnings Growth YOY 0.00%
Annual Earnings Growth -75.26%
Reported EPS 12 Trailing Months -3.68
Reported EPS Past Year -2.67
Reported EPS Prior Year -2.66
Net Income Twelve Trailing Months -162,722,041
Net Income Past Year -111,779,105
Net Income Prior Year -63,779,116
Quarterly Revenue Growth YOY 0.00%
5-Year Revenue Growth 0.00%
Operating Margin Twelve Trailing Months 0.00%

Balance Sheet

Total Cash Most Recent Quarter 74,252,000
Total Cash Past Year 22,514,823
Total Cash Prior Year 30,662,774
Net Cash Position Most Recent Quarter -245,997,000
Net Cash Position Past Year -75,212,313
Long Term Debt Past Year 97,727,136
Long Term Debt Prior Year 37,035,411
Total Debt Most Recent Quarter 320,249,000
Equity to Debt Ratio Past Year 0.54
Equity to Debt Ratio Most Recent Quarter 0.27
Total Stockholder Equity Past Year 115,619,035
Total Stockholder Equity Prior Year 139,769,322
Total Stockholder Equity Most Recent Quarter 116,963,000

Free Cash Flow

Free Cash Flow Twelve Trailing Months -144,892,132
Free Cash Flow Per Share Twelve Trailing Months -3.13
Free Cash Flow Past Year -83,716,621
Free Cash Flow Prior Year -53,909,897

Options

Put/Call Ratio 7.03
Has Options Options Chain
Liquidity Rating

Technical Analysis

Yahoo Finance Chart Yahoo Finance Chart
MACD 1.87
MACD Signal 2.71
20-Day Bollinger Lower Band 43.91
20-Day Bollinger Middle Band 88.43
20-Day Bollinger Upper Band 132.95
Beta 0.38
RSI 48.81
50-Day SMA 47.54
150-Day SMA 24.87
200-Day SMA 0.00

System

Modified 2/6/2026 7:49:54 PM EST